| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| KIM PETER S | Director | C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON | /s/ Jared Cohen, as Attorney-in-Fact | 18 Jun 2025 | 0001181180 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TRDA | Common Stock | Purchase | $367,010 | +25,000 | +37% | $14.68 | 92,412 | 13 May 2024 | Direct | F1, F2 |
| transaction | TRDA | Common Stock | Purchase | $364,672 | +25,000 | +27% | $14.59 | 117,412 | 14 May 2024 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F2 | On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.465 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |